Purpose: To assess the safety, tolerability and clinical benefit of local bladder hyperthermia (HT) and intravesical mitomycin-C (MMC) as second-line treatment of recurrent non-invasive transitional cell carcinoma (TCC) of the bladder.
Methods: Up to 18 patients with biopsy proven non-muscle invasive TCC of the bladder (Ta, T1, Tis) recurrent after at least one round of adjuvant treatment or an inability to tolerate BCG will be accrued to this study. Intravesical chemotherapy is administered per the standard instillation practices using 40 mg MMC diluted in 40 mL of sterile water. The temperature of the drug solution is monitored with a sensor inside the Foley. The MMC solution is maintained in the bladder concurrent with HT for at least 40 minutes (but not more than 60 minutes) of heating (40 -43 0 C). The patient may hold the medication in the bladder for a total of 2 hours. HT is delivered using the BSD 2000/Sigma Ellipse heating device. Treatment schedule consists of 6 weekly sessions (Induction) followed by 4 monthly sessions (Maintenance) until documented second recurrence. The primary endpoint is the occurrence of each of the following toxicity events: frequent urination, painful urination, flu-like symptoms, skin rash, fever/chills, myelosuppression, and bladder fibrosis/contraction. The secondary endpoint, time to second recurrence of UC of the bladder, will be addressed through exploratory analysis due to small sample sizes.
Results: This is an ongoing study and the results will be presented and updated at the time of the meeting. Ten patients have been enrolled on this trial. Five patients have finished induction (6 weekly sessions) and were assessed 4 weeks post-induction. Four out of five had no evidence of disease after cystoscopy and cytology. The treatment has been well tolerated with no Grade 3 or 4 toxicity. Initial experience shows that superficial bladder cancer treatment with intravesical MMC and external HT is well tolerated and without any adverse events to date. BSD 2000 heating system with Sigma Ellipse applicator is an effective and safe method for delivering local bladder HT to heat intravesical MMC within therapeutic temperature range of 40°C to 44°C.
Conclusion:
In patients with recurrent bladder cancer following initial standard adjuvant therapy, the response to second line therapies remains poor. External HT and intravesical MMC might prove to be safe and effective alternative.
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